Skip to main content
SpringerLink
Log in

Lingguizhugan Decoction, a Chinese herbal formula, improves insulin resistance in overweight/obese subjects with non-alcoholic fatty liver disease: a translational approach

  • Research Article
  • Published:
Frontiers of Medicine Aims and scope Submit manuscript

Abstract

Lingguizhugan Decoction (LGZG) has been investigated in basic studies, with satisfactory effects on insulin resistance in non-alcoholic fatty liver disease (NAFLD). This translational approach aimed to explore the effect and underlying mechanism of LGZG in clinical setting. A randomized, double-blinded, placebo-controlled trial was performed. A total of 243 eligible participants with NAFLD were equally allocated to receive LGZG (two groups: standard dose and low dose) or placebo for 12 weeks on the basis of lifestyle modifications. The primary efficacy variable was homeostasis model assessment of insulin resistance (HOMA-IR). Analyses were performed in two populations in accordance with body mass index (BMI; overweight/obese, BMI ⩾ 24 kg/m2; lean, BMI < 24 kg/m2). For overweight/obese participants, low-dose LGZG significantly decreased their HOMA-IR level compared with placebo (−0.19 (1.47) versus 0.08 (1.99), P = 0.038). For lean subjects, neither dose of LGZG showed a superior effect compared with placebo. Methylated DNA immunoprecipitation sequencing and real-time qPCR found that the DNA N6-methyladenine modification levels of protein phosphatase 1 regulatory subunit 3A (PPP1R3A) and autophagy related 3 (ATG3) significantly increased after LGZG intervention in overweight/obese population. Low-dose LGZG effectively improved insulin resistance in overweight/obese subjects with NAFLD. The underlying mechanism may be related to the regulation of DNA N6-methyladenine modification of PPP1R3A and ATG3. Lean subjects may not be a targeted population for LGZG.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64(1): 73–84

    Article  PubMed  Google Scholar 

  2. Zhou F, Zhou J, Wang W, Zhang XJ, Ji YX, Zhang P, She ZG, Zhu L, Cai J, Li H. Unexpected rapid increase in the burden of NAFLD in china from 2008 to 2018: a systematic review and meta-analysis. Hepatology 2019; 70(4): 1119–1133

    Article  PubMed  Google Scholar 

  3. Wu Y, Zheng Q, Zou B, Yeo YH, Li X, Li J, Xie X, Feng Y, Stave CD, Zhu Q, Cheung R, Nguyen MH. The epidemiology of NAFLD in Mainland China with analysis by adjusted gross regional domestic product: a meta-analysis. Hepatol Int 2020; 14(2): 259–269

    Article  PubMed  Google Scholar 

  4. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G, Melchionda N. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107(5): 450–455

    Article  CAS  PubMed  Google Scholar 

  5. Seppälä-Lindroos A, Vehkavaara S, Häkkinen AM, Goto T, Wester-backa J, Sovijärvi A, Halavaara J, Yki-Järvinen H. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002; 87(7): 3023–3028

    Article  PubMed  Google Scholar 

  6. Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, Ponti V, Pagano G, Ferrannini E, Rizzetto M. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005; 48(4): 634–642

    Article  CAS  PubMed  Google Scholar 

  7. Ercin CN, Dogru T, Genc H, Celebi G, Aslan F, Gurel H, Kara M, Sertoglu E, Tapan S, Bagci S, Rizzo M, Sonmez A. Insulin resistance but not visceral adiposity index is associated with liver fibrosis in nondiabetic subjects with nonalcoholic fatty liver disease. Metab Syndr Relat Disord 2015; 13(7): 319–325

    Article  CAS  PubMed  Google Scholar 

  8. Fujii H, Imajo K, Yoneda M, Nakahara T, Hyogo H, Takahashi H, Hara T, Tanaka S, Sumida Y, Eguchi Y, Chayama K, Nakajima A, Nishimoto N, Kawada N; Japan Study Group of Nonalcoholic Fatty Liver Disease. HOMA-IR: an independent predictor of advanced liver fibrosis in nondiabetic non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2019; 34(8): 1390–1395

    Article  CAS  PubMed  Google Scholar 

  9. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362(18): 1675–1685

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67(1): 328–357

    Article  PubMed  Google Scholar 

  11. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL—EASD—EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64(6): 1388–1402

    Article  Google Scholar 

  12. Billington EO, Grey A, Bolland MJ. The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis. Diabetologia 2015; 58(10): 2238–2246

    Article  CAS  PubMed  Google Scholar 

  13. Musso G, Cassader M, Paschetta E, Gambino R. Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis. JAMA Intern Med 2017; 177(5): 633–640

    Article  PubMed  PubMed Central  Google Scholar 

  14. Centis E, Marzocchi R, Suppini A, Dalle Grave R, Villanova N, Hickman IJ, Marchesini G. The role of lifestyle change in the prevention and treatment of NAFLD. Curr Pharm Des 2013; 19(29): 5270–5279

    Article  CAS  PubMed  Google Scholar 

  15. Liu T, Yang LL, Zou L, Li DF, Wen HZ, Zheng PY, Xing LJ, Song HY, Tang XD, Ji G. Chinese medicine formula Linggui-zhugan decoction improves beta-oxidation and metabolism of fatty acid in high-fat-diet-induced rat model of fatty liver disease. Evid Based Complement Alternat Med 2013; 2013: 429738

    PubMed  PubMed Central  Google Scholar 

  16. Yang L, Lin W, Nugent CA, Hao S, Song H, Liu T, Zheng P. Lingguizhugan decoction protects against high-fat-diet-induced nonalcoholic fatty liver disease by alleviating oxidative stress and activating cholesterol secretion. Int J Genomics 2017; 2017: 2790864

    Article  PubMed  PubMed Central  Google Scholar 

  17. Zhu M, Hao S, Liu T, Yang L, Zheng P, Zhang L, Ji G. Lingguizhugan decoction improves non-alcoholic fatty liver disease by altering insulin resistance and lipid metabolism related genes: a whole trancriptome study by RNA-Seq. Oncotarget 2017; 8(47): 82621–82631

    Article  PubMed  PubMed Central  Google Scholar 

  18. Dang Y, Hao S, Zhou W, Zhang L, Ji G. The traditional Chinese formulae Ling-gui-zhu-gan decoction alleviated non-alcoholic fatty liver disease via inhibiting PPP1R3C mediated molecules. BMC Complement Altern Med 2019; 19(1): 8

    Article  PubMed  PubMed Central  Google Scholar 

  19. Dang Y, Xu J, Yang Y, Li C, Zhang Q, Zhou W, Zhang L, Ji G. Ling-gui-zhu-gan decoction alleviates hepatic steatosis through SOCS2 modification by N6-methyladenosine. Biomed Pharmacother 2020; 127: 109976

    Article  CAS  PubMed  Google Scholar 

  20. Ye Q, Zou B, Yeo YH, Li J, Huang DQ, Wu Y, Yang H, Liu C, Kam LY, Tan XXE, Chien N, Trinh S, Henry L, Stave CD, Hosaka T, Cheung RC, Nguyen MH. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2020; 5(8): 739–752

    Article  PubMed  Google Scholar 

  21. Sookoian S, Pirola CJ. Systematic review with meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients. Aliment Pharmacol Ther 2017; 46(2): 85–95

    Article  CAS  PubMed  Google Scholar 

  22. Kumar R, Mohan S. Non-alcoholic fatty liver disease in lean subjects: characteristics and implications. J Clin Transl Hepatol 2017; 5(3): 216–223

    PubMed  PubMed Central  Google Scholar 

  23. Li H, Chen Y, Tian X, Hong Y, Chen C, Sharokh NK, Jiao J. Comparison of clinical characteristics between lean and obese nonalcoholic fatty liver disease in the northeast Chinese population. Arch Med Sci Atheroscler Dis 2019; 4(1): e191–e195

    Article  PubMed  PubMed Central  Google Scholar 

  24. Niriella MA, Kasturiratne A, Pathmeswaran A, De Silva ST, Perera KR, Subasinghe SKCE, Kodisinghe SK, Piyaratna TACL, Vithiya K, Dassanayaka AS, De Silva AP, Wickramasinghe AR, Takeuchi F, Kato N, de Silva HJ. Lean non-alcoholic fatty liver disease (lean NAFLD): characteristics, metabolic outcomes and risk factors from a 7-year prospective, community cohort study from Sri Lanka. Hepatol Int 2019; 13(3): 314–322

    Article  PubMed  Google Scholar 

  25. National Pharmacopoeia Committee. Chinese Pharmacopoeia (part I). Beijing: China Medical Science and Technology Press, 2015

    Google Scholar 

  26. Xu J, Wang R, You S, Zhang L, Zheng P, Ji G, Liu B. Traditional Chinese medicine Lingguizhugan decoction treating non-alcoholic fatty liver disease with spleen-yang deficiency pattern: study protocol for a multicenter randomized controlled trial. Trials 2020; 21(1): 512

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010; 340(mar23 1): c332

    Article  PubMed  PubMed Central  Google Scholar 

  28. Cheng CW, Wu TX, Shang HC, Li YP, Altman DG, Moher D, Bian ZX; CONSORT-CHM Formulas 2017 Group. CONSORT extension for Chinese herbal medicine formulas 2017: recommendations, explanation, and elaboration. Ann Intern Med 2017; 167(2): 112–121

    Article  PubMed  Google Scholar 

  29. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67(1): 328–357

    Article  PubMed  Google Scholar 

  30. Digestive Disease Branch of China Association of Chinese Medicine. Expert consensus on diagnosis and treatment of spleen deficiency pattern in traditional Chinese medicine. J Tradit Chin Med (Zhong Yi Za Zhi) 2017; 58(17): 1525–1530 (in Chinese)

    Google Scholar 

  31. Zhao P, Li XT. Study of systematic evaluation on the literature of spleen-deficiency syndrome diagnostic standard. Liaoning J Tradit Chin Med (Liaoning Zhong Yi Za Zhi) 2013; 40(7): 1304–1306 (in Chinese)

    Google Scholar 

  32. Zheng XY. Guidelines for clinical research of new Chinese medicine (on trial). Beijing: China Medical Science and Technology Press, 2002

    Google Scholar 

  33. Department of Disease Control, Ministry of Health, People’s Republic of China. Guidelines for prevention and control of overweight and obesity in Chinese adults. Beijing: People’s Medical Publishing House, 2006

    Google Scholar 

  34. Li MY. Clinical experience of the application of the original classical prescriptions. Forum Tradit Chin Med (Guo Yi Lun Tan) 2013; 28(1): 3–6 (in Chinese)

    Google Scholar 

  35. Tang XD, Bian LQ, Gao R. Exploration into the preparation of placebos used in Chinese medicinal clinical trial. Chin J Integr Tradit West Med (Zhongguo Zhong Xi Yi Jie He Za Zhi) 2009; 29(7): 656–658 (in Chinese)

    Google Scholar 

  36. Papamiltiadous ES, Roberts SK, Nicoll AJ, Ryan MC, Itsiopoulos C, Salim A, Tierney AC. A randomised controlled trial of a Mediterranean dietary intervention for adults with non alcoholic fatty liver disease (MEDINA): study protocol. BMC Gastroenterol 2016; 16(1): 14

    Article  PubMed  PubMed Central  Google Scholar 

  37. Ware JEJr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30(6): 473–483

    Article  PubMed  Google Scholar 

  38. Zung WW. A self-rating depression scale. Arch Gen Psychiatry 1965; 12(1): 63–70

    Article  CAS  PubMed  Google Scholar 

  39. Zung WW. A rating instrument for anxiety disorders. Psychosomatics 1971; 12(6): 371–379

    Article  CAS  PubMed  Google Scholar 

  40. Liu LP, Li R, Zhang LD, Zhang LC, Xu S. Effect of Linggui Zhugan Tang on hepatic FXR/FGF15/SHP pathway in ob/ob mice with leptin-deficient. Chin J Exp Tradit Med Formulae (Zhongguo Shi Yan Fang Ji Xue Za Zhi) 2018; 24(22): 107–111 (in Chinese)

    Google Scholar 

  41. Cai H, Scott E, Kholghi A, Andreadi C, Rufini A, Karmokar A, Britton RG, Horner-Glister E, Greaves P, Jawad D, James M, Howells L, Ognibene T, Malfatti M, Goldring C, Kitteringham N, Walsh J, Viskaduraki M, West K, Miller A, Hemingway D, Steward WP, Gescher AJ, Brown K. Cancer chemoprevention: evidence of a nonlinear dose response for the protective effects of resveratrol in humans and mice. Sci Transl Med 2015; 7(298): 298ra117

    Article  PubMed  PubMed Central  Google Scholar 

  42. Iyer LM, Abhiman S, Aravind L. Natural history of eukaryotic DNA methylation systems. Prog Mol Biol Transl Sci 2011; 101: 25–104

    Article  CAS  PubMed  Google Scholar 

  43. Ahrens M, Ammerpohl O, von Schönfels W, Kolarova J, Bens S, Itzel T, Teufel A, Herrmann A, Brosch M, Hinrichsen H, Erhart W, Egberts J, Sipos B, Schreiber S, Häsler R, Stickel F, Becker T, Krawczak M, Röcken C, Siebert R, Schafmayer C, Hampe J. DNA methylation analysis in nonalcoholic fatty liver disease suggests distinct disease-specific and remodeling signatures after bariatric surgery. Cell Metab 2013; 18(2): 296–302

    Article  CAS  PubMed  Google Scholar 

  44. Gerhard GS, Malenica I, Llaci L, Chu X, Petrick AT, Still CD, DiStefano JK. Differentially methylated loci in NAFLD cirrhosis are associated with key signaling pathways. Clin Epigenetics 2018; 10(1): 93

    Article  PubMed  PubMed Central  Google Scholar 

  45. Iacobazzi V, Castegna A, Infantino V, Andria G. Mitochondrial DNA methylation as a next-generation biomarker and diagnostic tool. Mol Genet Metab 2013; 110(1–2): 25–34

    Article  CAS  PubMed  Google Scholar 

  46. Hao Z, Wu T, Cui X, Zhu P, Tan C, Dou X, Hsu KW, Lin YT, Peng PH, Zhang LS, Gao Y, Hu L, Sun HL, Zhu A, Liu J, Wu KJ, He C. N6-Deoxyadenosine methylation in mammalian mitochondrial DNA. Mol Cell 2020; 78(3): 382–395.e8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Yao B, Cheng Y, Wang Z, Li Y, Chen L, Huang L, Zhang W, Chen D, Wu H, Tang B, Jin P. DNA N6-methyladenine is dynamically regulated in the mouse brain following environmental stress. Nat Commun 2017; 8(1): 1122

    Article  PubMed  PubMed Central  Google Scholar 

  48. Delibegovic M, Armstrong CG, Dobbie L, Watt PW, Smith AJ, Cohen PT. Disruption of the striated muscle glycogen targeting subunit PPP1R3A of protein phosphatase 1 leads to increased weight gain, fat deposition, and development of insulin resistance. Diabetes 2003; 52(3): 596–604

    Article  CAS  PubMed  Google Scholar 

  49. Hansen L, Reneland R, Berglund L, Rasmussen SK, Hansen T, Lithell H, Pedersen O. Polymorphism in the glycogen-associated regulatory subunit of type 1 protein phosphatase (PPP1R3) gene and insulin sensitivity. Diabetes 2000; 49(2): 298–301

    Article  CAS  PubMed  Google Scholar 

  50. Song S, Tan J, Miao Y, Li M, Zhang Q. Crosstalk of autophagy and apoptosis: involvement of the dual role of autophagy under ER stress. J Cell Physiol 2017; 232(11): 2977–2984

    Article  CAS  PubMed  Google Scholar 

  51. Zhou B, Liu J, Kang R, Klionsky DJ, Kroemer G, Tang D. Ferroptosis is a type of autophagy-dependent cell death. Semin Cancer Biol 2020; 66: 89–100

    Article  CAS  PubMed  Google Scholar 

  52. Huang DW, Shen SC, Wu JS. Effects of caffeic acid and cinnamic acid on glucose uptake in insulin-resistant mouse hepatocytes. J Agric Food Chem 2009; 57(17): 7687–7692

    Article  CAS  PubMed  Google Scholar 

  53. Li JE, Futawaka K, Yamamoto H, Kasahara M, Tagami T, Liu TH, Moriyama K. Cinnamaldehyde contributes to insulin sensitivity by activating PPARδ, PPARγ, and RXR. Am J Chin Med 2015; 43(5): 879–892

    Article  CAS  PubMed  Google Scholar 

  54. Ali NM, Mahmoud AAA, Mahmoud MF, El Fayoumi HM. Glycyrrhizic acid and silymarin alleviate the neurotoxic effects of aluminum in rats challenged with fructose-induced insulin resistance: possible role of toll-like receptor 4 pathway. Drug Chem Toxicol 2019; 42(2): 210–219

    Article  CAS  PubMed  Google Scholar 

  55. Eu CH, Lim WY, Ton SH, bin Abdul Kadir K. Glycyrrhizic acid improved lipoprotein lipase expression, insulin sensitivity, serum lipid and lipid deposition in high-fat diet-induced obese rats. Lipids Health Dis 2010; 9(1): 81

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This study is supported by the National Natural Science Foundation of China (No. 816220108030), the Evidence-based Capacity Building Project for Basic Traditional Chinese Medicine-Specialized Diseases (No. 2019XZZX-XH012), and Shanghai Three-year Action Plan for Accelerating the Development of Traditional Chinese Medicine (ZY(2018-2020)-CCCX-2002-01).

Author information

Author notes

  1. These authors contributed equally to this work.

Authors and Affiliations

  1. Institute of Digestive Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China

    Liang Dai, Jingjuan Xu, Yanqi Dang, Linda L. D. Zhong, Wenjun Zhou & Guang Ji

  2. Clinical Research Academy, Peking University Shenzhen Hospital, Shenzhen, 518032, China

    Liang Dai

  3. Department of Integrated Traditional and Western Medicine, Jinling Hospital, Medical School of Nanjing University, Nanjing, 210002, China

    Jingjuan Xu

  4. Shanghai Innovation Centre of TCM Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China

    Baocheng Liu, Ruirui Wang, Jianying Wang & Lei Zhang

  5. Sanlin Health Centre of Pudong New District, Shanghai, 200120, China

    Lijie Zhuang

  6. Zhangjiang Health Centre of Pudong New District, Shanghai, 201203, China

    Dong Li

  7. Beicai Health Centre of Pudong New District, Shanghai, 201204, China

    Lulu Jiao

  8. Hong Kong Chinese Medicine Study Centre, Hong Kong Baptist University, Hong Kong, 999077, China

    Linda L. D. Zhong

Authors
  1. Liang Dai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jingjuan Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Baocheng Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yanqi Dang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ruirui Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lijie Zhuang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Dong Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Lulu Jiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jianying Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Lei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Linda L. D. Zhong
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Wenjun Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Guang Ji
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Guang Ji.

Ethics declarations

Liang Dai, Jingjuan Xu, Baocheng Liu, Yanqi Dang, Ruirui Wang, Lijie Zhuang, Dong Li, Lulu Jiao, Jianying Wang, Lei Zhang, Linda L.D. Zhong, Wenjun Zhou, and Guang Ji declare that they have no conflict of interest. The study protocol was approved by the Medical Ethics Committee of Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine (No. 2017LCSY069) and registered at the Chinese Clinical Trial Registry (No. ChiCTR1800014364) on January 8, 2018. All three health centers acknowledged the ethical approval from the Medical Ethics Committee of Longhua Hospital. This trial was conducted strictly following the Helsinki Declaration. All participants provided a written inform consent before entering the study.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dai, L., Xu, J., Liu, B. et al. Lingguizhugan Decoction, a Chinese herbal formula, improves insulin resistance in overweight/obese subjects with non-alcoholic fatty liver disease: a translational approach. Front. Med. 16, 745–759 (2022). https://doi.org/10.1007/s11684-021-0880-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11684-021-0880-3

Keywords

Search

Navigation